Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ACET 10.31.2024

Full Press ReleaseSEC FilingsOur ACET Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
  • 12.31.2024 - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
  • 12.19.2024 - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Recent Filings

  • 12.19.2024 - EX-99.1 EX-99.1
  • 12.19.2024 - 8-K Current report
PDF Version

REDWOOD CITY, Calif.&BOSTON--(BUSINESS WIRE)--Oct. 31, 2024--Adicet Bio, Inc.(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards onOctober 31, 2024.

Three individuals were hired by Adicet inOctober 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 59,800 shares of Adicet’s common stock with an exercise price of$1.28per share, the closing price of Adicet’s common stock as reported by Nasdaq onOctober 31, 2024. One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of each recipient’s start date and thereafter the remaining three-fourths of the shares underlying each employee’s option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient’s start date, in each case, subject to each such employee’s continued employment with Adicet on such vesting dates.

All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors inJanuary 2022and subsequently amended inJanuary 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

AboutAdicet Bio, Inc.

Adicet Bio, Inc.is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website athttps://www.adicetbio.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241031738321/en/

Adicet Bio, Inc.Investor and Media ContactsInvestors:Anne Bowdidgeabowdidge@adicetbio.com

Janhavi MohitePrecision AQ212-362-1200janhavi.mohite@precisionaq.com

Media:Kerry Beth Dalykbdaly@adicetbio.com

Source:Adicet Bio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com